About the Company
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on CHAMPIONS ONCOLOGY, INC.
Is Champions Oncology, Inc.'s (NASDAQ:CSBR) Recent Stock Performance ...
Champions Oncology's (NASDAQ:CSBR) stock is up by a considerable 24% over the past three months. As most would know, fundamentals are what usually guide market price movements over the long-term ...
Champions Oncology, Inc. (CSBR) Upgraded to Buy: What Does It ... - Nasdaq
Earnings Estimate Revisions for Champions Oncology, Inc. This company is expected to earn $0.06 per share for the fiscal year ending April 2021, which represents a year-over-year change of 150%.
Champions Oncology, Inc.'s (NASDAQ:CSBR) 11% gain last week benefited ...
Every investor in Champions Oncology, Inc. (NASDAQ:CSBR) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 30% to be ...
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2024 Earnings Call Transcript
Champions Oncology, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.17. Operator: Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 ...
Champions Oncology Announces a Multi-Year Agreement and Strategic ...
Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, today announced an agreement to adopt ...
Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q1 2020 Results ...
Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2020 Results Earnings Conference Call September 16, 2019 4:30 PM ETCompany ParticipantsRonnie Morris - Chief ...
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates
Champions Oncology, Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $12.77 million for the quarter ended January 2023, surpassing the Zacks Consensus Estimate by 2.26%.
Champions Oncology, Inc.: Champions Oncology Reports Record Annual ...
About Champions Oncology, Inc. Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations.
Champions Oncology, Inc. (CSBR) Reports Next Week: What You Should Expect
Champions Oncology, Inc. (CSBR) is expected to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended July 2021.
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2025 Earnings Call Transcript
Champions Oncology, Inc. beats earnings expectations. Reported EPS is $0.05, expectations were $0.01. Operator: Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 ...
Similar Companies
Loading the latest forecasts...